170 related articles for article (PubMed ID: 36096509)
1. A case of multiple primary lung adenocarcinoma with a CD74-NRG1 fusion protein and HER2 mutation benefit from combined target therapy.
Chen K; Li W; Xi X; Zhong J
Thorac Cancer; 2022 Nov; 13(21):3063-3067. PubMed ID: 36096509
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
Cadranel J; Liu SV; Duruisseaux M; Branden E; Goto Y; Weinberg BA; Heining C; Schlenk RF; Cheema P; Jones MR; Drilon A; Trombetta D; Muscarella LA; Tolba K; Gounant V; Cseh A; Solca F; Laskin JJ; Renouf DJ
Oncologist; 2021 Jan; 26(1):7-16. PubMed ID: 32852072
[TBL] [Abstract][Full Text] [Related]
3. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.
Laskin J; Liu SV; Tolba K; Heining C; Schlenk RF; Cheema P; Cadranel J; Jones MR; Drilon A; Cseh A; Gyorffy S; Solca F; Duruisseaux M
Ann Oncol; 2020 Dec; 31(12):1693-1703. PubMed ID: 32916265
[TBL] [Abstract][Full Text] [Related]
4. Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case.
Gow CH; Wu SG; Chang YL; Shih JY
Med Oncol; 2014 Jul; 31(7):34. PubMed ID: 24913807
[TBL] [Abstract][Full Text] [Related]
5. Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report.
Nie X; Zhang P; Bie Z; Song C; Zhang M; Ma D; Cui D; Cheng G; Li H; Lei Y; Su X; Wu W; Li L
World J Surg Oncol; 2023 Aug; 21(1):246. PubMed ID: 37587479
[TBL] [Abstract][Full Text] [Related]
6. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.
Jones MR; Lim H; Shen Y; Pleasance E; Ch'ng C; Reisle C; Leelakumari S; Zhao C; Yip S; Ho J; Zhong E; Ng T; Ionescu D; Schaeffer DF; Mungall AJ; Mungall KL; Zhao Y; Moore RA; Ma Y; Chia S; Ho C; Renouf DJ; Gelmon K; Jones SJM; Marra MA; Laskin J
Ann Oncol; 2017 Dec; 28(12):3092-3097. PubMed ID: 28950338
[TBL] [Abstract][Full Text] [Related]
7. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
Shin DH; Jo JY; Han JY
Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
[TBL] [Abstract][Full Text] [Related]
8. Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions.
Liu SV; Frohn C; Minasi L; Fernamberg K; Klink AJ; Gajra A; Savill KMZ; Jonna S
Lung Cancer; 2024 Feb; 188():107469. PubMed ID: 38219288
[TBL] [Abstract][Full Text] [Related]
9. Plain language summary of NRG1 fusions in cancer: current knowledge and treatment with afatinib and other drugs.
Liu SV
Future Oncol; 2022 Aug; 18(26):2865-2870. PubMed ID: 35876504
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung.
Shin DH; Lee D; Hong DW; Hong SH; Hwang JA; Lee BI; You HJ; Lee GK; Kim IH; Lee YS; Han JY
Oncotarget; 2016 Oct; 7(43):69450-69465. PubMed ID: 27626312
[TBL] [Abstract][Full Text] [Related]
11. Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population.
Pan Y; Zhang Y; Ye T; Zhao Y; Gao Z; Yuan H; Zheng D; Zheng S; Li H; Li Y; Jin Y; Sun Y; Chen H
J Thorac Oncol; 2019 Nov; 14(11):2003-2008. PubMed ID: 31382039
[TBL] [Abstract][Full Text] [Related]
12. Successful targeting of the
Wu X; Zhang D; Shi M; Wang F; Li Y; Lin Q
Ann Transl Med; 2021 Oct; 9(19):1507. PubMed ID: 34805369
[TBL] [Abstract][Full Text] [Related]
13. CD74-NRG1 fusions in lung adenocarcinoma.
Fernandez-Cuesta L; Plenker D; Osada H; Sun R; Menon R; Leenders F; Ortiz-Cuaran S; Peifer M; Bos M; Daßler J; Malchers F; Schöttle J; Vogel W; Dahmen I; Koker M; Ullrich RT; Wright GM; Russell PA; Wainer Z; Solomon B; Brambilla E; Nagy-Mignotte H; Moro-Sibilot D; Brambilla CG; Lantuejoul S; Altmüller J; Becker C; Nürnberg P; Heuckmann JM; Stoelben E; Petersen I; Clement JH; Sänger J; Muscarella LA; la Torre A; Fazio VM; Lahortiga I; Perera T; Ogata S; Parade M; Brehmer D; Vingron M; Heukamp LC; Buettner R; Zander T; Wolf J; Perner S; Ansén S; Haas SA; Yatabe Y; Thomas RK
Cancer Discov; 2014 Apr; 4(4):415-22. PubMed ID: 24469108
[TBL] [Abstract][Full Text] [Related]
14. Plain language summary of publication: new information for the potential role of afatinib in treating people with
Cadranel J
Future Oncol; 2022 Jun; 18(18):2193-2200. PubMed ID: 35400204
[TBL] [Abstract][Full Text] [Related]
15. VAMP2-NRG1 Fusion Gene is a Novel Oncogenic Driver of Non-Small-Cell Lung Adenocarcinoma.
Jung Y; Yong S; Kim P; Lee HY; Jung Y; Keum J; Lee S; Kim J; Kim J
J Thorac Oncol; 2015 Jul; 10(7):1107-11. PubMed ID: 26134228
[TBL] [Abstract][Full Text] [Related]
16. NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma.
Duruisseaux M; McLeer-Florin A; Antoine M; Alavizadeh S; Poulot V; Lacave R; Rabbe N; Cadranel J; Wislez M
Cancer Med; 2016 Dec; 5(12):3579-3585. PubMed ID: 27770508
[TBL] [Abstract][Full Text] [Related]
17. A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib.
Cheema PK; Doherty M; Tsao MS
J Thorac Oncol; 2017 Dec; 12(12):e200-e202. PubMed ID: 29169524
[No Abstract] [Full Text] [Related]
18. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic
Odintsov I; Lui AJW; Sisso WJ; Gladstone E; Liu Z; Delasos L; Kurth RI; Sisso EM; Vojnic M; Khodos I; Mattar MS; de Stanchina E; Leland SM; Ladanyi M; Somwar R
Clin Cancer Res; 2021 Jun; 27(11):3154-3166. PubMed ID: 33824166
[TBL] [Abstract][Full Text] [Related]
19. Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database.
Ptáková N; Martínek P; Holubec L; Janovský V; Vančurová J; Grossmann P; Navarro PA; Rodriguez Moreno JF; Alaghehbandan R; Hes O; Májek O; Pešek M; Michal M; Ondič O
Genes Chromosomes Cancer; 2021 Jul; 60(7):474-481. PubMed ID: 33583086
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic KRAS promotes growth of lung cancer cells expressing SLC3A2-NRG1 fusion via ADAM17-mediated shedding of NRG1.
Shin DH; Kim SH; Choi M; Bae YK; Han C; Choi BK; Kim SS; Han JY
Oncogene; 2022 Jan; 41(2):280-292. PubMed ID: 34743207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]